natgillin/translations-raw huggingface dataset:
The compound for use according to claim 4 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau. 
Formulacija u skladu sa patentnim zahtjevom 8 gdje je interferon odabran od interferona alfa 2B, pegiliranog interferona alfa, konsenzusnog interferona, interferona alfa 2A, i limfoblastičnog interferona tau.
C is a protecting group selected from the group consisting of monofunctional protecting groups that are suitable for the protection of an aliphatic hydroxyl group; and wherein step (2) of the process is performed in the presence of an iodine(V) species; or wherein step (2) of the process is performed in the presence of a transition metal compound, and wherein the transition metal compound is present in an amount of 0.1 mol% to 50 mol% with respect to compound III. 
C je zaštitna skupina odabrana iz skupine koju čine monofunkcionalne zaštitne skupine koje su prikladne za zaštitu alifatske hidroksilne skupine; 1 pri čemu se korak (2) postupka provodi u prisutnosti vrste joda (V); ili pri čemu se korak (2) postupka provodi u prisutnosti spoja prijelaznog metala, pri čemu je spoj prijelaznog metala prisutan u količini od 0,1 mol% do 50 mol% u odnosu na spoj HI.
A method for the treatment of a substrate comprising carbohydrate material, optionally a plant material, which method comprises contacting the substrate with a polypeptide according to claim 1 and/or a composition according to claim 9. 
Postupak za obradu supstrata koji sadrži ugljikohidratni materijal, ma potrebi biljni materijal, naznačen time da postupak obuhvaća dovođenje u kontakt supstrata s polipeptidom prema zahtjevu 1 i/ili pripravkom prema zahtjevu 9.
The mixture was filtered and the solvent removed to give a yellow solid which was recrystallised from ethyl acetate to give the title compound (D1) (168 g, 97%) as a yellow solid; 
Smjesu se filtrira, a otapalo ukloni kako bi se dobilo žutu krutinu, koju se prekristalizira iz etil-acetata kako bi se dobilo naslovni spoj (D1) (168 g, 97 %) u obliku žute krutine;
The method according to claim 1 or claim 2, wherein a TGF-beta inhibitor is additionally present in the medium and, optionally, wherein the TGF-beta inhibitor is a small molecule inhibitor selected from the group consisting of: A83-01, SB-431542, SB-505124, SB-525334, LY 364947, SD-208, SJN 2511. 
Postupak prema zahtjevu 1 ili 2, pri čemu se TGF-beta inhibitor dodatno nalazi u mediju, i opcionalno, pri čemu TGF-beta inhibitor je inhibitor male molekule izabran iz grupe koja obuhvaća: A83-01, SB-431542, SB-505124,
The use of the protein Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) or fragments of their amino acid sequence, or the modified protein, for prognosis and/or diagnosis of Trisomy 21 (Down syndrome) during pregnancy. 
Primjena proteinskog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. P02743) za prognozu i/ili dijagnozu trisomije 21 (Down-ovog sindroma) za vrijeme trudnoće.
A process according to any of claims 23 to 26, wherein a sealing shoe matching the shape of the peripheral flange is used to seal the lidding film to the sealable container. 
Postupak prema bilo kojem od Zahtjeva 18 do 21, gdje se za spajanje filma poklopca za posudu koja se može hermetički zatvoriti, koristi potkovica za spajanje čiji oblik odgovara obliku prirubnice.
The insert for soles according to claim 1, characterized in that it has a permeability to water vapor that is at least equal to 9 mg/cm2·h determined according to the method presented in chapter 6.6 of the ISO 20344-2004 standard. 
Umetak za potplate u skladu s patentnim zahtjevom 1, naznačen time, da ima propusnost za vodenu paru koja je najmanje jednaka 9 mg/cm".h, određeno u skladu s metodom prikazanom u poglavlju 6.6 standarda ISO 20.344-
Package according to any preceding claim, characterized in that the vial is filled with cells in lyophilized form or in liquid suspension or in any other form according to the type of cells and the conservation method and the bag is filled with a culture medium. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, da je bočica napunjena stanicama u liofiliziranom obliku ili u tekućoj suspenziji ili u bilo kojem drugom obliku prema vrsti stanica 1 postupku konzerviranja, a vrećica je napunjena podlogom.
The method of item 3, in which the initial dose is 0.1 mg/kg of rhASM. 
KSM za uporabu sukladno patentnom zahtjevu 2, pri čemu je inicijalna doza 0,1 mg/kg rhKSM.
A nucleic acid encoding an optimized viral polypeptide having the amino acid sequence set forth in SEQ ID NO: 21 and/or SEQ ID NO: 22. 
Cjepivo prema zahtjevu 5 ili 6, gdje spomenuto cjepivo nadalje sadrži vektor koji kodira optimizirani env polipeptid koji ima sekvencu prikazanu u SEQ ID NO: 10.
This problem with the manufacture of a veneer which is a precise, however complex and highly wasteful process, is intensified by the fact that the starting material "wood" respectively "tree" is a natural product. 
Ovaj problem s proizvodnjom furnira, koja proizvodnja zahtijeva precizan postupak, ali i složen postupak s mnogo otpada, pojačava se činjenicom daje polazni materijal "drvo", odnosno "drveće", prirodni proizvod.
welding or joining the edges together. A method as claimed in claim 7 wherein the blown film multi-layer polymeric material comprises at least one barrier layer. 
Postupak izrade fleksibilne ambalažne tube opisan u patentnom zahtjevu 7, naznačen time što višeslojni polimerni materijal sadrži barem jedan barijerni sloj.
wherein the groups A, D, E, G, R10, R30, R40, R50 and R60 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO—, (C1-C4)-alkyl-O— or halogen. 
Ho gsR" R gdje su skupine A, D, E, G, R'", R*", R", R* i R u spojevima formula II i III definirane kao u spojevima formule I, gdje uz to funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, a skupina J u spoju formule II je HO-, (C,-C,)-alkil-O- ili halogen.
Method according to Claim 1, characterized in that there are at least three part-flows and the said emission flow (a) is at essentially the maximum point of the velocity distribution of the gas flow. 
Postupak sukladno zahtjevu 1, naznačen time, da ima najmanje tri djelomična tijeka, a navedeni tijek emisije (a) nalazi se na maksimalnoj brzmi protoka plina.
modify the release rate of the first substance based on the determined amount of first substance. The apparatus of claim 1, wherein the housing is configured to enable a user to inhale the first substance. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kućište (112) konfigurirana tako da korisniku omogućuje udisanje prve tvari i pri čemu prva tvar sadrži nikotin.
The topical gel composition of claim 1, wherein the carbomer is selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980. 
Kompozicija topičkog gela prema zahtjevu 4, pri čemu je agonist alfa adrenergijskog receptora izabran iz grupe koja se sastoji od oksimetazolina, fenilefrina, metoksiamina, brimonidina, tetrahidrozolina, nafazolina, ksilometazolina, epinefrina, i norepinefrina.
Use according to any of claims 13 to 15 where the compound is to be administered via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 13 do 15, naznačena time što je navedeni spoj namijenjen primjeni putem razdavača medikamenta, kojeg se bira između inhalatora sa suhim prahom u spremniku, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
at least one light source configured to emit light in a predefined pattern that indicates a predetermined position with respect to the image sensor for placement of the form. 
Sustav prema patentnom zahtjevu 1, naznačen time, da se barem jedna oznaka interpretira u skladu sa svojim položajem s obzirom na sliku.
The transdermal delivery device of claims 1-3, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (∑-caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 4, naznačen time da se mikrosfere sastoje u osnovi od opioid antagonista i polimera izabranog iz skupine koje se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, kitosana, poli (I-kaprolaktona), polianhidrida, albumina, njihovih smjesa i kopolimera.
Apparatus as claimed in claim 17, wherein the intermediate portion (73,73') comprises three angled sections (73a, 73b, 73c). 
Uređaj u skladu s patentnim zahtjevom 17, kod kojega srednji dio (73, 73') ima tri sekcije koje su pod kutom (73a, 73b, 73c).
A mixing member as claimed in Claim 3, characterized in that the scraper (8) extends astride said outer lateral edge (4b) of the longitudinal blade (4). 
Članak za miješanje prema patentnom zahtjevu 1, naznačen time, da navedeni strugač (8) zahvaća udubinu ili uleknuće (4c), formirano u bočnoj strani uzdužne lopatice (4).
A kit, comprising: an intrafallopian contraceptive delivery device comprising a control device (582, 665), a catheter (292, 581, 660) extending from the control device, and an intrafallopian device coupled to the catheter; and 
Komplet, obuhvaća: intrafalopijanu napravu za unos kontraceptiva koja obuhvaća kontrolnu napravu (582, 665), kateter (292, 581, 660) koji se proteže iz kontrolne naprave 1 intrafalopijalnu napravu povezanu s kateterom; i stabilizacijsku napravu (200) kako je definirana u patentnom zahtjevu 1.
A Plasto-ferrite plate as used in example 1 was engraved on a computer-controlled mechanical engraving station with text (see FIG. 
Na ploču izrađenu od Plastoferrita koja je korištena u primjeru 1 ugravira se tekst na računalno nadziranoj mehaničkoj postaji za graviranje (vidi Sliku 4).
NCIMB 42012; and any combination of two or more thereof; 
NCIMB 42012; ili bilo koja kombinacija dva ili više navedenih.
to 40 wt.%, preferably 25 to 35 wt.% of water, and 
do 40 težinskih postotaka, poželjno 25 do 35 težinskih postotaka vode i
The topical composition for use according to claim 12 which comprises Coriolus versicolor extract, Azadirachta indica extract, carboxymethyl beta-glucan, hialuronic acid, Alpha-glucan oligosaccharide, magnolol, honokiol, Centella asiatica extract and aloe vera. 
Pripravak za lokalnu primjenu za uporabu sukladno zahtjevu 12, naznačen time, da sadrži ekstrakt Coriolus versicolor, ekstrakt Azadirachta indica, karboksimetil beta-glukan, hijaluronsku kiselinu, alfa-glukan oligosaharid, magnolol, honokiol, ekstrakt Centella asiatica i aloe veru.
In a more specific embodiment, the combination therapies of this invention include co-administrering a compound of Formula Ib and a second therapeutic agent selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir, saquinavir, lopinavir, nevirapine, emtricitaine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vicrviroc, pharmaceutically acceptable salts of any of the foregoing, and combinations thereof to treat HIV infection in a patient in need thereof. 
Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
The gene of any one of claims 1-3, wherein the amino acid sequence encoded by the modified EGFR gene consists of SEQ ID NO: 3. 
Gen iz bilo kojeg zahtjeva 1 do 3, pri čemu se sekvenca aminokiselina, kodirana modificiranim EGFR genom sastoji od SEQ ID NO: 3.
The binding molecule of claim 1 or 2 or the composition of claim 6 for use in therapy. 
Vežuća molekula u skladu s patentnim zahtjevom 1 ili 2, ili pripravak u skladu s patentnim zahtjevom 6, naznačeni time što su namijenjeni upotrebi u terapiji.
contacting the A9-tetrahydrocannabinol from step (b) with a non-polar organic solvent and optionally its enantiomer to form the first composition. 
kontaktiranje trans-(-)-A9-tetrahidrokanabinola iz koraka (b) sa trans-(+)-A9-tetrahidrokanabinolom i nepolarnim organskim otapalom tako da formiraju prvi sastav;
systemic (oral and/or parenteral) steroid treatment, or an increase in inhaled corticosteroids to at least 4 times the last dose received prior to discontinuation, or 
(i) sistemsko (oralno i/ili parenteralno) steroidno liječenje, ili (ii) povećanje inhalacijskih kortikosteroida do najmanje 4 puta posljednje doze primljene prije prekida, ili (1ii) hospitalizaciju.
A blister package comprising a chewing gum composition according to any one of claims 1 - 7. 
Blister pakiranje, naznačeno time što sadrži pripravak u obliku žvakaće gume u skladu s bilo kojim od patentnih zahtjeva 1-7.
The monoclonal antibody or the antigen-binding portion according to item 10, wherein said inflammatory disease is selected from the group consisting of vasculitis, arthritis, sepsis, septic shock, endotoxic shock, toxic shock syndrome, acquired respiratory distress syndrome, glomerulonephritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, peritonitis, nephritis and psoriasis. 
Monoklonalno protutijelo ili njegov dio koji se veže na antigen prema zahtjevu 7, naznačen/o time, da je spomenuta upalna bolest odabrana iz skupine koju čine vaskulitis, artritis, sepsa, septički šok, endotoksički šok, sindrom toksičkog šoka, sindrom stečenog respiratornog poremećaja, glomerulonefritis, upalna bolest crijeva, Chronova bolest, ulcerativni kolitis, peritonitis, nefritis i psorijaza.
lipophilic extract of Zingiber officinale obtained by extraction with carbon dioxide under supercritical conditions; and extract of Cynara scolymus for the preparation of a composition for the reduction of postprandial drowsiness. 
Upotreba a) lipofilnog ekstrakta Zingiber officinale dobivenog ekstrakcijom s ugljičnim dioksidom pod superkritičnim uvjetima, te b) ekstrakta Cynura scolymus, naznačena time da je za preparaciju prirpavaka za smanjivanje pospanosti nakon obroka.
Support according to claim 9, characterized in that the support comprises, in a region of the contact surface of the wall fastening segment, at least one tab. 
Konzola (100) prema barem jednom od prethodnih patentnih zahtjeva, naznačena time, da je konzola (100) oblikovana u jednom komadu.
The footing according to claim 6, further comprising a front element that can be associated with the front side of said supporting structure and is provided with a box-like structure, constituted by a molded covering made of technopolymer mounted on a plate and ergonomically contoured in order to contain instruments for the control and actuation of the machine. 
Postolje u skladu s patentnim zahtjevom 1, naznačeno time, da obuhvaća prednji element (13) koji se može povezati s prednjom stranom navedene nosive konstrukcije (2) i ima kutijastu strukturu koja je načinjena od oblikovanog poklopca izrađenog od tehnopolimera montiranog na ploči i ergonomski oblikovana kako bi sadržavao instrumente za upravljanje i pokretanje stroja.
The compound of claim 43 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1Helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
Process of activation of a landfill of municipal solid waste (MSW) dried to a humidity content lower than 20%, characterised in that it provides for the feeding of water into the landfill until humidity contents of around 30-60% are reached and triggering of a process of anaerobic digestion with production of biogas (40-50% methane). 
Postupak aktivacije odlagališta komunalnog krutog otpada (MSW), čiji je sadržaj vlage pomoću aerobne obrade spušten ispod 20% težinski, koji je položen na vodo-nepropusnu podlogu (T) i prekriven po vrhu slojem gline niske propusnosti na plinove i tekućine, naznačen time da se dovođenjem vode u odlagalište podigne sadržaj vlage na 30-60% težinski, i time izazove anaerobno razlaganje i razvijanje bioplina koji sadrži 40-50%metana,
± 1.5 cholesterol (mmol. 
Ukupan kolesterol (mmol.L-1)
The compound for use of claim 27, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Spoj za uporabu prema zahtjevu 27, naznačen time da je metabolički poremećaj prekomjerna težina, gojaznost, otpornost na inzulin, dijabetes tipa Il, hiperlipidemija, žučni kamenac, angina, hipertenzija, kratak dah, tahikardija, neplodnost, apneja u snu, bol u leđima 1 zglobovima, proširene vene, ili osteoartritis.
A system according to claim 1, wherein the second circuitry and software components comprise: 
Sustav sukladno zahtjevu 1, naznačen time da drugi sklop i softverske komponente sadrže: a. - čip flash memorije; b.
Unless the trifluoroacetyl group present in the compounds of formula (6) has been cleaved off during the abovementioned oxidation process, it can be removed by treatment of the resulting intermediate with a suitable base, such as a carbonate of an alkali or earth alkali metal, preferably potassium carbonate, in a suitable alcohol, such as an aliphatic alcohol C1-C6-alkyl-OH, preferably methanol. 
nakon čega slijedi, ako u gore navedenom procesu oksidacije trifluoracetilna skupina koja je prisutna u spoju s formulom (6) nije odcijepljena, uklanjanje navedene trifluoracetilne skupine obradom dobivenog intermedijera sa pogodnom bazom u alkoholnom otapalu, da se dobije spoj s formulom (I), u kojem R? je vodik, B* R*
The solution was allowed to warm to rt and then stirred overnight. 
Mješavina je ostavljena da se zagrije na sobnu temperaturu i potom preko noći miješana.
is hydrogen, halogen, -CN, OH, optionally substituted (C1-C6)alkyl, optionally substituted (C3-C8)cycloalkyl, optionally substituted (C1-C6) alkoxy, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclo; 
je vodik, halogen, -CN, OH, po izboru supstituiran (C1-C6)alkil, po izboru supstituiran (C3-C8)cikloalkil, po izboru supstituiran (C1-C6) alkoksi, po izboru supstituiran aril, po izboru supstituiran heteroaril ili po izboru supstituiran heterociklo;
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a temperature that is set at 36±0.9 °C, wherein the cell culture is a continuous culture maintained at a density of 1.4x106 to 2.8x106 cells/ml, and wherein the mammalian cell is a CHO cell. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X ± 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
The recovered labeled peptide is further purified by reverse phase HPLC on a Vydac C-18 analytical column (The Separations Group, Hesperia, Calif.) on a Beckman 334 gradient HPLC system using a gradient of acetonitrile in 0.1% TFA. 
Prikupljeni obilježeni peptid daljnje je pročišćen HPLC-om u obratnoj fazi, na analitičkom stupcu Vidac C-18 (The Separations Group, Hesperia, CA), na sustavu za gradijentni HPLC Beckman 334, uz eluiranje gradijentom acetonitrila u 0,1 % TFA.
contacting the aqueous medium provided in step a) with the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate obtained in step d). The process according to claim 1, wherein the source of ground calcium carbonate (GCC) is selected from marble, chalk, calcite, dolomite, limestone and mixtures thereof and/or the precipitated calcium carbonate (PCC) is selected from one or more of the aragonitic, vateritic and calcitic mineralogical crystal forms. 
Postupak za smanjenje nepoželjnih tvari u vodenom mediju koje su nastale u postupku proizvodnje papira ili proizvodnje pulpe, naznačen time da sadrži slijedeće korake: a) osiguravanje vodenog medija koji sadrži nepoželjne tvari nastale u postupku proizvodnje papira ili proizvodnje pulpe; b) osiguravanje prirodnog kalcijevog karbonata i/ili taložnog kalcijevog karbonata, pri čemu je izvor prirodnog kalcijevog karbonata (GCC) odabran od mramora, krede, kalcita, dolomita, vapnenca i njihovih smjesa i/ili taložni kalcijev karbonat (PCC) je odabran od jednog ili više od aragonitnih, vateritnih i kalcitnih mineraloških kristalnih oblika;
A pharmaceutically acceptable salt of a compound of formula 
Spoj koji ima strukturnu formulu Ic:
The method according to claim 1, wherein the polyacrylonitrile copolymers are selected from the group consisting of polyacrylonitrile copolymers with a polyacrylonitrile content of 85% by weight or more, mixtures and blends thereof. 
Metoda prema nekom od gore navedenih zahtjeva, naznačena time da su celuloza i/ili derivati celuloze odabrani iz skupine koja se sastoji od celuloznog karbamata, celuloznog alofanata i hemiceluloze; i/ili njihovih mješavina ili spojeva.
The combination as defined in claim 4 wherein the compound of formula I is present in a weight ratio to the antidiabetic agent within the range from about 0.01 to about 300:1. 
Kombinacija prema patentnom zahtjevu 4, naznačena time što je spoj formule I prisutan u odnosu masa prema antidijabetičnom sredstvu unutar opsega od oko 0.01 do oko 300:1.
Composed element according to any of the preceding claims, characterized in that it comprises a locking element (15) at the tongue (13) in the form of a projection having a locking surface (142). 
Složeni element u skladu s patentnim zahtjevom 1 ili 2, karakteriziran na način da je element zaključavanja (15) na jezičku (13) potpuno smješten u materijalu odgovarajućeg vanjskog sloja (136).
The above-defined method for the reconstruction of a tooth may generally comprise some or all of the steps outlined in Example 9. 
Gore definirana metoda za rekonstrukciju zuba može općenito sadržavati neke ili sve korake prikazane u Primjeru 9.
is attached at the 5 or 6 position of the benzimidazole and represents 
R, je vezan na položaj 5 ili 6 u benzimidazolu i predstavlja
is selected from the group consisting of nitro, cyano, methyl, trifluoromethyl, —C(═O)T1, —C(═O)OT4 and —S(═O)2T4; 
gdje je izabran iz skupine koja se sastoji od nitro, cijano, trifluormetila i -C(=O)OT4;
applying, on top of at least part of the said substrate surface, a coating layer comprising orientable flake pigment particles and a curable, transparent binder; 
nanošenje, preko najmanje dijela površine navedenog supstrata, premaznog sloja koji sadrži čestice usmjerivog ljuskastog pigmenta (3) i transparentno vezivno sredstvo koje se može otvrdnuti;
The catalyst according to claim 2, wherein the supported metal catalyst is a supported rhodium catalyst having a structure shown in the following formula (IV): 
Uporaba prema patentnom zahtjevu 12 ili 13, naznačena time što molarni omjer podržanog metalnog katalizatora prema spoju prikazanom u formuli (V) iznosi 1:50 ∼ 2000.